nature portfolio

Corresponding author(s):	Tingjun Hou, Chang-Yu Hsieh, Dongsheng Cao
Last undated by author(s):	13 02 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section

.51	a:	tι	SI	П	CS
	-	٠.	_	٠.	-

n/a	onfirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
×	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
×	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Sof	ware and code

Policy information about availability of computer code

Data collection

No software was used for data collection.

Data analysis

The models were implemented using python (3.7) with dgl-cuda11.0(0.7.1), hyperopt (0.2.7) and pytorch (1.11.0). The data processing and metrics calculation were implemented using python (3.7) with scikit-learn (1.0.2), numpy (1.21.5), pandas (1.3.5).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The ESOL, Mutagenicity, hERG and BBBP datasets are available at https://github.com/wzxxxx/Structure-Mask-Explanation--SME-.

<u>Human rese</u>	arch partio	zipants		
Policy information	about <u>studies in</u>	volving human research participants and Sex and Gender in Research.		
Reporting on sex and gender This information		This information has not been collected.		
Population charact	eristics	See above.		
Recruitment		See above.		
Ethics oversight		See above.		
Note that full informa	ation on the appro	val of the study protocol must also be provided in the manuscript.		
Field-spe	ecific re	porting		
•		the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
	the document with a	chavioural & social sciences		
Lite scier	nces stu	ıdy design		
All studies must dis	sclose on these p	points even when the disclosure is negative.		
Sample size	(ESOL, Mutagen	ize calculation was performed. We evaluated our method on the four benchmarks and the molecules size of the four benchmarks genicity, hERG and BBBP) is 1111, 7672, 9876 and 1859, respectively. These datasets are widely used to build predictive models of operties, indicating that such sample sizes are sufficient.		
Data exclusions	No data were ex	e excluded from the analyses.		
Replication		ask, we construct 10 sub-models with different random seeds and ensemble them to obtain the final ensemble model. Since we casks, we have replicated 40 sub-models in total. All attempts at replication were successful.		
Randomization	Each dataset is r	is randomly split into the training set, validation set, and test set by a ratio of 8:1:1.		
Blinding	Investigators were not blinded to group allocation during experiments and outcome analysis.			
We require informatis system or method lis Materials & ex n/a Involved in the Antibodies	on from authors a ted is relevant to y perimental sy ne study	bout some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, our study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Stems Methods n/a Involved in the study ChIP-seq Involved in the study Involve		
Eukaryotic cell lines Palaeontology and archaeology				

Animals and other organisms

Dual use research of concern

Clinical data